In vitro Assessment of the Effects of Silybin on CYP2B6-mediated Metabolism

Abstract

Silybin is a flavonol compound with a variety of physiological properties, such as hepatoprotective, anti-fibrogenic, and hypocholesterolemic effects. Although the in vivo and in vitro effects of silybin are frequently reported, studies on herb–drug interactions have yet to be performed. With the discovery of multiple important substrates of CYP2B6 recently, there is a growing body of evidence indicating that CYP2B6 plays a much larger role in human drug metabolism than previously thought.

The purpose of this study is to determine how silybin affects the CYP2B6 enzymeʼs activity, as well as to clarify the molecular mechanisms for inhibition by silybin. The results showed that silybin inhibited CYP2B6 activity in liver microsomes in a non-competitive manner, with IC₅₀ and K_i values of 13.9 µM and 38.4 µM, respectively. Further investigations revealed that silybin could down-regulate the expression of CYP2B6 protein in HepaRG cells. The hydrogen bond conformation of silybin in the active site of the CYP2B6 isoform was revealed by a molecular docking study. Collectively, our findings verify that silybin is an inhibitor of CYP2B6 and explain the molecular mechanism of inhibition. This can lead to a better understanding of the herb–drug interaction between silybin and the substrates of the CYP2B6 enzyme, as well as a more rational clinical use of silybin.

Key words

silybin - Silybum marianum - CYP2B6 - inhibition - Liver microsomes - Interaction

Publication History

Received: 18 October 2022

Accepted after revision: 23 May 2023

Accepted Manuscript online:
26 May 2023

Article published online:
14 July 2023

• References

• 1 Bijak M. Silybin, a major bioactive component of milk thistle (Silybum marianum L. Gaernt.)-chemistry, bioavailability, and metabolism. Molecules (Basel, Switzerland) 2017; 22: 1942
• 2 Federico A, Dallio M, Loguercio C. Silymarin/silybin and chronic liver disease: A marriage of many years. Molecules (Basel, Switzerland) 2017; 22: 191
• 3 Loguercio C, Festi D. Silybin and the liver: From basic research to clinical practice. World J Gastroenterol 2011; 17: 2288-2301
• 4 Binienda A, Ziolkowska S, Pluciennik E. The anticancer properties of silibinin: Its molecular mechanism and therapeutic effect in breast cancer. Anticancer Agents Med Chem 2020; 20: 1787-1796
• 5 DiCenzo R, Shelton M, Jordan K, Koval C, Forrest A, Reichman R, Morse G. Coadministration of milk thistle and indinavir in healthy subjects. Pharmacotherapy 2003; 23: 866-870
• 6 Zhang S, Yang X, Morris ME. Combined effects of multiple flavonoids on breast cancer resistance protein (ABCG2)-mediated transport. Pharm Res 2004; 21: 1263-1273
• 7 Dobiasová S, Řehořová K, Kučerová D, Biedermann D, Káňová K, Petrásková L, Koucká K, Václavíková R, Valentová K, Ruml T, Macek T, Křen V, Viktorová J. Multidrug resistance modulation activity of silybin derivatives and their anti-inflammatory potential. Antioxidants (Basel, Switzerland) 2020; 9: 455
• 8 Hedrich WD, Hassan HE, Wang H. Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B 2016; 6: 413-425
• 9 Li L, Zhang QY, Ding X. A CYP2B6-humanized mouse model and its potential applications. Drug Metab Pharmacokinet 2018; 33: 2-8
• 10 Křen V, Marhol P, Purchartová K, Gabrielová E, Modrianský M. Biotransformation of silybin and its congeners. Curr Drug Metab 2013; 14: 1009-1021
• 11 Gufford BT, Metzger IF, Bamfo NO, Benson EA, Masters AR, Lu JBL, Desta Z. Influence of CYP2B6 Pharmacogenetics on Stereoselective Inhibition and Induction of Bupropion Metabolism by Efavirenz in Healthy Volunteers. J Pharmacol Exp Ther 2022; 382: 313-326
• 12 Zhou S, Yung Chan S, Cher Goh B, Chan E, Duan W, Huang M, McLeod HL. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet 2005; 44: 279-304
• 13 Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 2013; 138: 103-141
• 14 Pekthong D, Desbans C, Martin H, Richert L. Bupropion hydroxylation as a selective marker of rat CYP2B1 catalytic activity. Drug Metab Dispos 2012; 40: 32-38
• 15 Zhang B, Jiang G, Wang L, Li X, Zhao C, Tan Q, Kang W, Feng Y, Han X, Raza HK, Mao Y. An analysis of silybin meglumine tablets in the treatment of drug-induced liver injury as assessed for causality with the updated Roussel Uclaf Causality Assessment Method using a nationwide database. Br J Clin Pharmacol 2023; 89: 1329-1337
• 16 Turpeinen M, Tolonen A, Chesne C, Guillouzo A, Uusitalo J, Pelkonen O. Functional expression, inhibition and induction of CYP enzymes in HepaRG cells. Toxicol In Vitro 2009; 23: 748-753
• 17 Mooiman KD, Maas-Bakker RF, Moret EE, Beijnen JH, Schellens JH, Meijerman I. Milk thistleʼs active components silybin and isosilybin: Novel inhibitors of PXR-mediated CYP3A4 induction. Drug Metab Dispos 2013; 41: 1494-1504
• 18 Desta Z, Saussele T, Ward B, Blievernicht J, Li L, Klein K, Flockhart DA, Zanger UM. Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro . Pharmacogenomics 2007; 8: 547-558
• 19 Hedrich WD, Xiao J, Heyward S, Zhang Y, Zhang J, Baer MR, Hassan HE, Wang H. Activation of the constitutive androstane receptor increases the therapeutic index of CHOP in lymphoma treatment. Mol Cancer Ther 2016; 15: 392-401
• 20 Nolan D, Phillips E, Mallal S. Efavirenz and CYP2B6 polymorphism: Implications for drug toxicity and resistance. Clin Infect Dis 2006; 42: 408-410
• 21 Nishiya Y, Hagihara K, Ito T, Tajima M, Miura S, Kurihara A, Farid NA, Ikeda T. Mechanism-based inhibition of human cytochrome P450 2B6 by ticlopidine, clopidogrel, and the thiolactone metabolite of prasugrel. Drug Metab Dispos 2009; 37: 589-593
• 22 Tu DZ, Mao X, Zhang F, He RJ, Wu JJ, Wu Y, Zhao XH, Zheng J, Ge GB. Reversible and irreversible inhibition of cytochrome P450 enzymes by Methylophiopogonanone A. Drug Metab Dispos 2020; 49: 459-469
• 23 Zhang F, Huang J, He RJ, Wang L, Huo PC, Guan XQ, Fang SQ, Xiang YW, Jia SN, Ge GB. Herb-drug interaction between Styrax and warfarin: Molecular basis and mechanism. Phytomedicine 2020; 77: 153287
• 24 Aninat C, Piton A, Glaise D, Le Charpentier T, Langouët S, Morel F, Guguen-Guillouzo C, Guillouzo A. Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells. Drug Metab Dispos 2006; 34: 75-83
• 25 Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (San Diego, Calif) 2001; 25: 402-408